{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=24", "query": { "condition": "Carcinoma, Renal", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 1550, "total_pages": 155, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Renal&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T08:42:44.481Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF9001", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-15", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597839" }, { "nct_id": "NCT00513175", "title": "Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplasia", "Acute Lymphoblastic Leukemia", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma", "Multiple Myeloma", "NHL", "Myeloproliferative Diseases", "Chronic Myeloid Leukemia", "Renal Cell Carcinoma", "Aplastic Anemia" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2001-10", "completion_date": "2007-11", "has_results": false, "last_update_posted_date": "2012-11-09", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513175" }, { "nct_id": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INC280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2012-02-29", "completion_date": "2017-07-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324479" }, { "nct_id": "NCT07179770", "title": "Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "89Zr-DFO-girentuximab", "type": "DRUG" }, { "name": "89Zr-DFO-girentuximab PET", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2025-09-15", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07179770" }, { "nct_id": "NCT01263769", "title": "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2011-02", "completion_date": "2023-06-05", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01263769" }, { "nct_id": "NCT05363280", "title": "Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Renal Cell Carcinoma (RCC)", "Non-Small Cell Lung" ], "interventions": [ { "name": "AL8326 40 mg", "type": "DRUG" }, { "name": "AL8326 60 mg", "type": "DRUG" }, { "name": "AL8326 80 mg--stopped", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advenchen Pharmaceuticals, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2022-11-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363280" }, { "nct_id": "NCT02655822", "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Cancer", "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Ciforadenant", "type": "DRUG" }, { "name": "Ciforadenant + atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2016-01", "completion_date": "2021-07", "has_results": false, "last_update_posted_date": "2021-08-30", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 15, "location_summary": "Tucson, Arizona • San Francisco, California • Stanford, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655822" }, { "nct_id": "NCT06630429", "title": "A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "Biospecimen Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-09-02", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630429" }, { "nct_id": "NCT02542202", "title": "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Renal Cell Cancer", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-05-01", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-05-30", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542202" }, { "nct_id": "NCT03793166", "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Lymph Nodes", "Metastatic Malignant Neoplasm in the Soft Tissue", "Metastatic Malignant Neoplasm in the Viscera", "Rhabdoid Tumor of the Kidney", "Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1175, "start_date": "2019-06-07", "completion_date": "2028-01-25", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T08:42:44.481Z", "location_count": 858, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03793166" } ] }